NCT00687219已完成3 期
Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 102
- 主要终点
- Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)
研究概览
简要总结
The objective is to evaluate the efficacy and safety of combination therapy with peginterferon alfa-2b 1.0 µg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks in participants with chronic hepatitis C and type C compensated liver cirrhosis. Participants who are hepatitis C virus ribonucleic acid (HCV-RNA) positive after 24 weeks of treatment will be discontinued from therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 20-70 years.
- •Positive quantitative serum HCV-RNA.
- •Participants classified as A in Child-Pugh classification, and who do not have ascites or hepatic encephalopathy.
- •Diagnosed with type C compensated liver cirrhosis based on liver biopsy performed within 3 years or latest celioscopy.
- •Prolonged prothrombin time by <=3.0 sec.
- •Participants and partners of participants willing to use adequate contraception during the course of the study.
- •Participants who can be hospitalized for at least 14 days since treatment initiation.
- •Weight >40 kg and <=100 kg
- •Hematology laboratory results of:
- •hemoglobin >=12 g/dL
- •neutrophil count >=1,500/mm^3
- •platelet count >=70,000/ mm^3
- •Blood chemistry results of:
- •albumin and direct bilirubin within normal limits
- •alpha fetoprotein (AFP) within reference range
- •AFP-L3<=10%
- •Protein induced by vitamin K (PIVKA)-II <=100 mAU/mL
排除标准
- •Participants who did not previously respond virologically to combination therapy with interferon (including polyethylene glycol-modified interferon) and ribavirin
- •Participants who had previously received treatment with interferon for whom at least 90 days have not elapsed since the end of previous treatment
- •Participants who have received treatment within 14 days prior to registration with injectable preparations containing glycyrrhizin/cysteine/glycyron or shosaikoto
- •Participants who have received administration of drugs having antiviral, anti-tumor, or immuno-modulating effect (including glucocorticoids and radiation therapy) within 90 days prior to registration (excluding local administration and topicals)
- •Participants who have received other investigational drugs within 180 days prior to registration
- •Hepatitis B surface (HBs) antigen positive
- •Antinuclear antibody >=320 times
- •Serum creatinine exceeding the upper limit of reference range
- •Participants with fasting blood glucose >=110 mg/dL (participants with fasting blood glucose >=110 mg/dL and <126 mg/dL can be registered if their hemoglobin A1C (HbA1c) is <6.5%) [fasting blood glucose should be measured when participants are not receiving treatment for diabetes mellitus]
- •Participants with any of the following: diabetes mellitus that requires treatment; thyroid function disorder not controlled by treatment; liver disease such as autoimmune, alcoholic and drug-induced liver diseases; hemophilia; arrhythmia requiring treatment; co-existing hypertension not controlled by drug therapy (systolic blood pressure [BP] >=160mmHg or diastolic BP>=100mmHg); chronic pulmonary disease; hemoglobinopathies (thalassemia, sickle cell anemia); malignant tumors or who have a history of malignant tumor within the past 5 years; organ transplants (other than cornea and hair transplant)
- •Participants with or who have a history of primary biliary cirrhosis, liver failure, hepatic carcinoma; decompensated liver cirrhosis with any the following diseases: ascites, jaundice, variceal hemorrhage, esophageal or gastric varices requiring treatment, hepatic encephalopathy, and idiopathic bacterial peritonitis; depression or schizophrenia requiring treatment, or suicidal attempt or suicidal ideation; epileptic seizures requiring treatment; angina, cardiac failure, myocardial infarction, or life-threatening arrhythmia; autoimmune disease (Hashimoto's disease, Crohn's disease, ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic erythematosus, autoimmune hemolytic anemia, scleroderma, etc.); hepatic carcinoma
- •Participants with a history of hypersensitivity to interferon preparations, biological products such as vaccine, or nucleoside analogs, and those with specific reaction to pegylated interferon alfa-2b in the prick test conducted before the initiation of treatment
- •Women who are pregnant or nursing as well as women for whom pregnancy cannot be ruled out by serum human chorionic gonadotropin (HCG) test conducted during the screening period. Male participants with partners who are pregnant.
研究组 & 干预措施
Peginterferon alfa-2b + Ribavirin
Experimental
干预措施: Peginterferon alfa-2b (Biological)
Peginterferon alfa-2b + Ribavirin
Experimental
干预措施: Ribavirin (Drug)
结局指标
主要结局
Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)
时间窗: Measured at 24 weeks after 48 weeks treatment (72 weeks)
Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)
次要结局
- Number of Participants With Undetectable HCV-RNA at Week 24(Week 24)
- Number of Participants With Undetectable HCV-RNA at End of Treatment(Up to 48 weeks)
研究者
相似试验
已完成
4 期
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous TherapiesChronic Hepatitis CHIV InfectionsNCT00530972Hospital Carlos III, Madrid50
已完成
3 期
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) InfectionHepatitis BNCT01368497National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)60
已完成
3 期
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)Chronic Hepatitis CLiver CirrhosisNCT00304551Chugai Pharmaceutical180
已完成
4 期
Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis CChronic Hepatitis CNCT01596517Asan Medical Center272
已完成
2 期
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected PatientsHepatitis C, ChronicTreatment FailureHIV InfectionsNCT00221650University Hospital, Bordeaux17